Next Article in Journal
Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
Next Article in Special Issue
Advances and Future Directions in Hepatobiliary Malignancies
Previous Article in Journal
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
Previous Article in Special Issue
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
 
 
Communication

Article Versions Notes

Curr. Oncol. 2023, 30(5), 5054-5061; https://doi.org/10.3390/curroncol30050382
Action Date Notes Link
article xml file uploaded 16 May 2023 07:47 CEST Original file -
article xml uploaded. 16 May 2023 07:47 CEST Update https://www.mdpi.com/1718-7729/30/5/382/xml
article pdf uploaded. 16 May 2023 07:47 CEST Version of Record https://www.mdpi.com/1718-7729/30/5/382/pdf
article html file updated 16 May 2023 07:48 CEST Original file https://www.mdpi.com/1718-7729/30/5/382/html
Back to TopTop